Results 131 to 140 of about 796 (164)
Some of the next articles are maybe not open access.
Cenobamate: A Review in Focal-Onset Seizures
CNS DrugsCenobamate (Ontozry®) is a once-daily oral antiseizure medication (ASM) approved in the EU for the adjunctive treatment of focal-onset seizures, with or without secondary generalisation, in adults with epilepsy that have not been adequately controlled despite previous treatment with ≥ 2 anti-epileptic drugs.
Tina, Nie, Sheridan M, Hoy
openaire +2 more sources
Cenobamate efficacy in specific populations
EpilepsiaAbstractMost people with epilepsy are able to achieve good seizure control with currently available medications. However, despite the development of more than 20 new antiseizure medications (ASMs) over the past 30 years, approximately one third of patients (both pediatric and adult) are treatment‐resistant and at risk of increased morbidity and ...
openaire +2 more sources
Efficacy of cenobamate in tumor‐related epilepsy
Epileptic DisordersAbstract Purpose Cenobamate is approved for treating focal epilepsy and has potential for treating tumor‐related epilepsy (TRE) based on potential anti‐tumor effects, though there is little data on efficacy and safety in this patient population.
Guido Chiriboga +8 more
openaire +2 more sources
Steps towards seizure freedom with the use of Cenobamate
Epilepsy & BehaviorCenobamate (CNB) is an antiseizure medication (ASM) that may change the prescription across the time. Our study sought to compare the rate of seizure-freedom patients after one year of CNB use experience in a single tertiary centre.All patients with a minimum follow-up of one year who used CNB between 2021 and 2022 (n = 66) were compared to those who ...
M, Toledo +8 more
openaire +2 more sources
Biocatalytic enantioselective synthesis of cenobamate, an antiepileptic drug
ChiralityAbstractA green and efficient process for the synthesis of cenobamate has been accomplished in 70% yield and >99% ee through the bio‐reduction of β‐ketotetrazole using Daucus carota whole plant cells. The corresponding β‐hydroxytetrazole was isolated in 60% yield and >98% ee.
Vennapusa Haritha +7 more
openaire +2 more sources
Effectiveness and tolerability of cenobamate: A single center experience
Epilepsy ResearchMedication-resistant epilepsy (MRE) is characterized by the failure of adequate trials of two antiseizure medications (ASMs). Numerous studies have shown that once two ASMs fail to control seizures, the likelihood of subsequent ASM regimens providing seizure control diminishes significantly. Recent clinical data on cenobamate (CNB) suggest it may offer
Christopher, Saouda +7 more
openaire +2 more sources
Cenobamate‐associated weight loss (Cenobaweight study)
EpilepsiaAbstractRationaleData on weight changes associated with Cenobamate (CNB) in patients with epilepsy is scarce. We performed a case‐control study because of concern for clinically significant weight loss.MethodsAll patients exposed to CNB between its May in February 2020 until October 2023 with at least 180 days of exposure were evaluated.
Jafar Hashem +6 more
openaire +2 more sources
[Cenobamate-a new perspective for epilepsy treatment].
Der Nervenarzt, 2021In spite of the introduction of numerous new antiseizure drugs (ASD) over the last decades, the percentage of drug-resistant epilepsies has remained almost stable. To achieve seizure freedom in such patients with any modified ASD regimen is an exception. Cenobamate (CNB) is a new ASD that showed unusually high efficacy in the pivotal placebo controlled,
openaire +1 more source
A Phase 1 Clinical Study Evaluating the Effects of Cenobamate on the QT Interval
Clinical Pharmacology in Drug Development, 2022Börje Darpo, Marc Kamin
exaly